BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its participation in the 33rd Congress of the European Academy of Dermatology and Venereology (EADV), taking place in Amsterdam from September 25 to 28, 2024. This year, Almirall marks its 80th anniversary, celebrating eight decades of innovation and commitment to delivering products positively impacting people’s health and lives..

西班牙巴塞罗那——（商业新闻短讯）——Almirall，S.A.（ALM），一家致力于医学皮肤病学的全球制药公司，今天宣布参加2024年9月25日至28日在阿姆斯特丹举行的欧洲皮肤病和性病学会（EADV）第33届大会。今年，Almirall迎来了80周年纪念日，庆祝了80年来的创新和致力于提供对人们的健康和生活产生积极影响的产品。。

At the congress, Almirall will present 34 abstracts detailing the latest research on lebrikizumab for moderate-to-severe atopic dermatitis in adolescents and adults, tildrakizumab and Almirall’s CAL/BDP cream for moderate-to-severe plaque psoriasis in adults, as well as tirbanibulin for actinic keratosis.

在大会上，Almirall将发表34篇摘要，详细介绍lebrikizumab治疗青少年和成人中度至重度特应性皮炎的最新研究，tildrakizumab和Almirall的CAL/BDP乳膏治疗成人中度至重度斑块状银屑病，以及替巴尼布林治疗光化性角化病。

The company will also host two symposia, providing a platform for experts to discuss current data, share insights, and facilitate discussions about the treatment of these chronic conditions with advanced biologics..

该公司还将举办两次研讨会，为专家提供一个平台，以讨论当前数据，分享见解，并促进有关使用先进生物制剂治疗这些慢性病的讨论。。

Impact of the treatment of psoriasis on patient wellbeing: new data from the POSITIVE study

银屑病治疗对患者健康的影响：来自实证研究的新数据

Almirall will unveil new interim data on the treatment of adults with moderate-to-severe plaque psoriasis with tidrakizumab at 52 weeks from the POSITIVE clinical study. The POSITIVE study is the first clinical trial in dermatology to use the WHO-5 Wellbeing Index as a primary endpoint. The 5-item World Health Organization Wellbeing Index is a validated questionnaire that assesses health-related subjective psychological wellbeing in a variety of chronic diseases.

。这项阳性研究是皮肤科首次将WHO-5健康指数作为主要终点的临床试验。世界卫生组织的5项幸福指数是一份经过验证的问卷，用于评估各种慢性病中与健康相关的主观心理幸福感。

The different sub-analyses presented during the congress reinforce the effectiveness of tildrakizumab on signs and symptoms in skin and beyond..

大会期间提出的不同子分析增强了tildrakizumab对皮肤及其他部位体征和症状的有效性。。

Almirall will host the symposium 'Advancing Psoriasis Management for Long-Term Patient Outcomes', featuring experts such as Prof. Dr. Diamant Thaçi from the University of Lübeck, Prof. Dr. Ulrich Mrowietz from the University Medical Center Schleswig-Holstein, and Prof. Anna López Ferrer from the Hospital de la Santa Creu i Sant Pau in Barcelona.

Almirall将主办“促进牛皮癣管理以实现长期患者预后”的研讨会，专家包括吕贝克大学的Diamant Thaçi教授，石勒苏益格-荷尔斯泰因大学医学中心的Ulrich Mrowietz教授和巴塞罗那圣克鲁医院的Anna López Ferrer教授。

The discussion will emphasize on the importance of tailoring treatments to individual patients, the latest real-world evidence, and practical strategies for clinical success managing psoriasis, with opportunities for interactive discussion with leading experts..

讨论将强调为个体患者量身定制治疗的重要性，最新的现实世界证据，以及临床成功管理牛皮癣的实用策略，并有机会与领先专家进行互动讨论。。

Advancing atopic dermatitis disease management

推进特应性皮炎疾病管理

Almirall will also present new data on lebrikizumab, a biologic approved for the treatment of moderate-to-severe atopic dermatitis. The late-breaking presentation will report lebrikizumab’s data over three years of continuous treatment, alongside new data on the rates of absolute endpoints and its effectiveness in patients inadequately controlled or ineligible for cyclosporine.

Almirall还将介绍lebrikizumab的新数据，lebrikizumab是一种被批准用于治疗中度至重度特应性皮炎的生物制剂。最新的报告将报告lebrikizumab在连续三年治疗中的数据，以及关于绝对终点率及其在控制不足或不符合环孢素治疗条件的患者中的有效性的新数据。

The Almirall symposium entitled 'Precision in AD: How Lebrikizumab is Changing the Treatment Paradigm' will feature the experts Marjolein Bruin-Weller, from the National Expertise Center for Atopic Dermatitis at the Department of Dermatology and Allergology of the University Medical Center Utrecht; Andrew Blauvelt from Portland, US, and Sascha Gerdes from the Center for Inflammatory Skin Diseases of the University Medical Center Schleswig-Holstein Campus Kiel.

题为“AD的精确性：Lebrikizumab如何改变治疗范式”的衣橱研讨会将由来自乌得勒支大学医学中心皮肤病学和变态反应学系国家特应性皮炎专业中心的专家Marjolein Bruin Weller参加；来自美国波特兰的安德鲁·布劳维尔特（AndrewBlauvelt）和来自石勒苏益格-荷尔斯泰因大学医学中心基尔校区炎症性皮肤病中心的萨莎·格德斯（SaschaGerdes）。

Discussions will focus on the clinical impact of lebrikizumab and offer a chance for participants to engage with leading specialists in this field..

讨论将集中在lebrikizumab的临床影响上，并为参与者提供与该领域领先专家接触的机会。。

Almirall celebrating 80 years of innovation

衣橱庆祝创新80周年

2024 marks a significant milestone for Almirall as the company celebrates 80 years of innovation and commitment to delivering impactful solutions to help improve patients’ lives. With a rich history in the pharmaceutical industry and a strong focus on medical dermatology, Almirall has built a robust pipeline addressing various diseases and using different therapeutic modalities.

2024年是Almirall的一个重要里程碑，该公司庆祝80年来的创新，并致力于提供有影响力的解决方案，以帮助改善患者的生活。凭借在制药行业的丰富历史和对医学皮肤病学的强烈关注，Almirall已经建立了一个强大的管道，用于解决各种疾病并使用不同的治疗方式。

Leading innovating in medical dermatology is enabled by Almirall's close collaboration with the dermatology community and patient-centric mindset. Celebrating its 80th anniversary, Almirall reaffirms its dedication to advancing skin science and developing novel treatments to benefit patients and the dermatology community around the world..

Almirall与皮肤病学界的密切合作和以患者为中心的思维方式，推动了医学皮肤病学的领先创新。在庆祝成立80周年之际，Almirall重申其致力于推进皮肤科学和开发新疗法，以造福世界各地的患者和皮肤病学界。。

For more information about Almirall’s 80th-anniversary celebrations, visit almirall80years.com

ANNEX: 33rd EADV Congress presentations and poster details:

附件：第33届EADV大会演示文稿和海报详情：

Satellite Symposium on psoriasis: Advancing Psoriasis Management for Long-Term Patient Outcomes

银屑病卫星研讨会：推进银屑病管理以获得长期患者结果

- Chair, Prof. Dr. Diamant Thaçi, Lübeck, Germany

-主席，Diamant Thaçi博士教授，德国吕贝克

- Prof. Dr. Anna López-Ferrer, Barcelona, Spain

-Anna López Ferrer教授博士，西班牙巴塞罗那

- Prof. Dr. Ulrich Mrowietz, Kiel, Germany

-Ulrich Mrowietz教授博士，德国基尔

Thursday 26th September at 17:45 (CEST) / Room G104-G105 (SAT 11.04).

9月26日星期四17:45（CEST）/G104-G105室（SAT 11.04）。

Satellite Symposium on atopic dermatitis: Precision in AD: how lebrikizumab is changing the treatment paradigm

特应性皮炎卫星研讨会：AD的精确度：lebrikizumab如何改变治疗范式

- Chair, Prof. Dr. Marjolein de Bruin-Weller, Utrecht, The Netherlands

-主席，荷兰乌得勒支Marjolein de Bruin Weller博士教授

- Dr. Andrew Blauvelt, Lake Oswego, US

-Andrew Blauvell博士，美国奥斯威戈湖。

- Prof. Dr. Sascha Gerdes, Kiel, Germany

-Sascha Gerdes教授，德国基尔

Friday 27th September at 13:00 (CEST) / Room G104-G105 (SAT 11.06).

9月27日星期五13:00（CEST）/G104-G105室（周六11:06）。

A total of 37 abstracts have been accepted by the EADV for their annual meeting.

EADV年会共接受了37篇摘要。

Ebglyss® (lebrikizumab)

象征® （利博利珠单抗）

1. Late breaking news: Efficacy and safety of lebrikizumab is maintained up to 3 years in patients with moderate-to-severe atopic dermatitis: ADvocate 1 and ADvocate 2 to ADjoin long-term extension trial

1、最新消息：lebrikizumab在中重度特应性皮炎患者中的疗效和安全性维持3年：ADvocate 1和ADvocate 2将进行长期延长试验

2. Absolute EASI response achieved by lebrikizumab over 16 weeks in patients with moderate-to-severe atopic dermatitis

2.lebrikizumab在16周内对中度至重度特应性皮炎患者的绝对EASI反应

3. Absolute itch and quality of life response with lebrikizumab through 52 weeks

3.lebrikizumab在52周内的绝对瘙痒和生活质量反应

4. Absolute EASI response achieved with lebrikizumab over 52 weeks in patients with moderate-to-severe atopic dermatitis

4.中度至重度特应性皮炎患者使用lebrikizumab在52周内达到绝对EASI反应

5. Absolute response of lebrikizumab at Week 52 in patients with moderate-to-severe atopic dermatitis who did not achieve protocol-defined response after initial 16 weeks of treatment

5.lebrikizumab在第52周对中度至重度特应性皮炎患者的绝对反应，这些患者在治疗最初16周后未达到方案规定的反应

6. Improvement across disease dimensions with lebrikizumab in combination with topical corticosteroids in atopic dermatitis inadequately controlled or ineligible to cyclosporine: results from the ADvantage study

6.lebrikizumab联合局部皮质类固醇治疗特应性皮炎控制不充分或不适合使用环孢菌素的疾病方面的改善：ADVARINCE研究的结果

7. Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients inadequately controlled or ineligible for cyclosporine: week 52 results of a phase 3 clinical study (ADvantage)

7.Lebrikizumab改善了未得到充分控制或不符合环孢素治疗条件的患者的中度至重度特应性皮炎的体征和症状：第52周3期临床研究的结果（ADvantage）

8. Lebrikizumab in monotherapy improves the signs of moderate-to-severe atopic dermatitis across different body regions including the head and neck over one year of treatment

单一疗法中的Lebrikizumab在一年的治疗中改善了包括头部和颈部在内的不同身体部位的中度至重度特应性皮炎的症状

9. Number needed to treat with lebrikizumab in monotherapy at Week 16 in patients with moderate-to-severe atopic dermatitis

9.中度至重度特应性皮炎患者在第16周单药治疗中需要使用lebrikizumab的数量

Ilumetri® (tildrakizumab)

专辑® （蒂尔德拉基苏马布）

1. Improving the well-being of patients with moderate to severe plaque psoriasis and involvement of impactful areas with Tildrakizumab

1.用Tildrakizumab改善中重度斑块状银屑病患者的健康状况和影响区域

2. Effectiveness and Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) of tildrakizumab patients with nail psoriasis: 52-week results from the phase IV POSITIVE Austrian subset.

2.tildrakizumab治疗银屑病和银屑病关节炎（NAPPA）的有效性和指甲评估指甲银屑病患者：IV期阳性奥地利亚组52周的结果。

3. Effectiveness of tildrakizumab in patients with moderate-to-severe psoriasis located in special areas: 52-week results from the POSITIVE study

3.tildrakizumab对位于特殊地区的中重度银屑病患者的有效性：阳性研究的52周结果

4. High effectiveness of tildrakizumab in bio-naïve and bio-experienced patients with moderate-to-severe psoriasis: 52-week results from the POSITIVE study

4.tildrakizumab在中重度银屑病的生物天真和生物经验患者中的高效性：阳性研究的52周结果

5. High effectiveness of tildrakizumab regardless of baseline characteristics in patients with moderate-to-severe psoriasis: 52-week results from the POSITIVE study

5、无论中重度银屑病患者的基线特征如何，tildrakizumab的高效性：阳性研究的52周结果

6. Patient-reported well-being using tildrakizumab for psoriasis in a real-world setting: 52-week interim data of the phase IV POSITIVE study

患者报告在现实环境中使用tildrakizumab治疗牛皮癣的幸福感：IV期阳性研究的52周中期数据

7. Safety of tildrakizumab in patients with moderate-to-severe psoriasis: 52-week data from the phase IV POSITIVE study

7.tildrakizumab在中重度银屑病患者中的安全性：来自IV期阳性研究的52周数据

8. Effectiveness of tildrakizumab for itch, pain, and fatigue in patients with moderate-to-severe psoriasis: 52-week results from the real-world POSITIVE study

8.tildrakizumab对中重度银屑病患者瘙痒、疼痛和疲劳的有效性：52周的真实阳性研究结果

9. Quality of life, work productivity and treatment satisfaction with tildrakizumab in moderate-to-severe psoriasis patients: 52-week interim data of the real-world POSITIVE study

9.中重度银屑病患者的生活质量，工作效率和对替拉单抗的治疗满意度：现实世界阳性研究的52周中期数据

10. Impact of patient psoriasis on partner well-being in a real-world setting: 52-week interim data of the phase IV POSITIVE study

银屑病患者在现实环境中对伴侣幸福感的影响：IV期阳性研究的52周中期数据

11. Efficacy and safety of tildrakizumab through Week 28 in patients with early vs late-onset moderate-to-severe plaque psoriasis: A post hoc analysis of reSURFACE 1 and reSURFACE 2

11.28周tildrakizumab治疗早期和晚期中重度斑块状银屑病患者的疗效和安全性：reSURFACE 1和reSURFACE 2的事后分析

Wynzora® (CAL/BDP)

温佐拉® （CAL/BDP）

1. Impact of calcipotriene and betamethasone dipropionate cream with PAD technology (CAL/BPD PAD cream) on scalp-PGA success, S-mPASI and clinician satisfaction among patients with mild-to-moderate scalp psoriasis in routine clinical practices in Europe. An interim analysis of the PRO-SCALP study.

1.在欧洲常规临床实践中，钙泊三烯和倍他米松二丙酸乳膏联合PAD技术（CAL/BPD PAD乳膏）对轻度至中度头皮牛皮癣患者头皮PGA成功率，S-mPASI和临床医生满意度的影响。PRO-头皮研究的中期分析。

2. Impact of calcipotriene and betamethasone dipropionate cream with PAD technology (CAL/BPD PAD cream) on patient symptoms, functioning, emotions, level of itching, and sleep quality among patients with mild-to-moderate scalp psoriasis in routine clinical practices in Europe. An interim analysis of the PRO-SCALP study..

2.在欧洲常规临床实践中，钙泊三烯和倍他米松二丙酸乳膏联合PAD技术（CAL/BPD PAD乳膏）对轻度至中度头皮牛皮癣患者症状，功能，情绪，瘙痒程度和睡眠质量的影响。亲头皮研究的中期分析。。

3. Patient preference over other topicals, perception of cream usability, treatment adherence and satisfaction among patients with mild-to-moderate scalp psoriasis using calcipotriene and betamethasone dipropionate cream with PAD technology (CAL/BPD PAD cream) in routine clinical practices in Europe.

3.在欧洲常规临床实践中，使用钙泊三烯和倍他米松二丙酸乳膏和PAD技术（CAL/BPD PAD乳膏），患者对其他局部用药的偏好，对乳膏可用性的看法，治疗依从性和满意度。

An interim analysis of the PRO-SCALP study..

亲头皮研究的中期分析。。

4. Best responders to calcipotriol and betamethasone dipropionate PAD-cream: post-hoc analysis from pooled MC2-01-C2 and MC2-01-C7 phase III trials at week 4 and week 8.

对卡泊三醇和倍他米松二丙酸软膏的最佳反应者：在第4周和第8周，来自合并的MC2-01-C2和MC2-01-C7 III期试验的事后分析。

5. Cost per responder analysis of calcipotriol plus betamethasone dipropionate cutaneous PAD cream for the topical treatment of mild to moderate plaque psoriasis in Italy.

在意大利，卡泊三醇加倍他米松二丙酸皮肤垫霜用于局部治疗轻度至中度斑块状银屑病的每反应者成本分析。

6. Patient benefit assessment of topical treatment in psoriasis: Validation of the PBI-TOP questionnaire in a longitudinal study.

银屑病局部治疗的患者益处评估：纵向研究中PBI-TOP问卷的验证。

Klisyri® (tirbanibulin) and actinic keratosis

Klisyri®（替巴尼布林）和光化性角化病

1. Lack of correlation between number of baseline actinic keratoses and local tolerability signs severity in patients treated with tirbanibulin over a 100 cm2 area: results from a Phase 3 study

1.在100 cm2面积内接受替巴尼布林治疗的患者中，基线光化性角化病的数量与局部耐受性体征严重程度之间缺乏相关性：第三阶段研究的结果

2. Real-world evidence of tirbanibulin for actinic keratosis in Germany. Insights into patient-reported outcomes, safety and effectiveness

德国替巴尼布林治疗光化性角化病的真实证据。洞察患者报告的结果，安全性和有效性

3. Efficacy and safety of tirbanibulin 1% ointment for the treatment of actinic keratosis in conditions close to routine clinical practice in Spain and Italy (TIRBASKIN study)

3.1%替巴尼布林软膏在西班牙和意大利接近常规临床实践的条件下治疗光化性角化病的疗效和安全性（TIRBASKIN研究）

4. Patient and physician-reported outcomes with tirbanibulin 1% ointment for actinic keratosis in conditions close to routine clinical practice in Spain and Italy (TIRBASKIN study)

患者和医生报告了在西班牙和意大利接近常规临床实践的情况下使用1%替巴尼布林软膏治疗光化性角化病的结果（TIRBASKIN研究）

5. Enhancement of sun-damaged skin qualities with tirbanibulin (SunDamage Study)

5、使用替巴尼布林增强受阳光伤害的皮肤质量（SunDamage研究）

6. Actinic cheilitis: Diagnosis and monitoring after treatment with Tirbanibulin using optical coherence tomography

光化性唇炎：使用光学相干断层扫描技术对替巴尼布林治疗后的诊断和监测

7. Diagnosis and treatment of patients with actinic keratosis in France: REAKT study Actinic keratosis in France: an avoidable risk of skin cancer, unexpectedly also for people aged under 65 years (REAKT study)

7、法国光化性角化病患者的诊断和治疗：REAKT研究法国光化性角化病：65岁以下人群可避免的皮肤癌风险（REAKT研究）

8. Actinic keratosis in France: disease perceptions, expectations, and behaviors of patients (REAKT study).

法国的光化性角化病：患者的疾病认知，期望和行为（REAKT研究）。

Poster availability date and time: From 25 September 2024 (07.00 CEST) until 3 months post congress.

海报发布日期和时间：从2024年9月25日（CEST 07.00）到国会召开后3个月。

Location: https://eadv.org/congress/, and e-poster area

Location: https://eadv.org/congress/, and e-poster area

About Almirall

阿尔米拉利

Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs..

Almirall是一家致力于医学皮肤病学的全球制药公司。我们与领先的科学家、医疗保健专业人员和患者密切合作，以实现我们的目标：通过帮助患者实现健康生活的希望和梦想，改变患者的世界。我们站在科学的最前沿，提供突破性的，差异化的医学皮肤病学创新，以满足患者的需求。。

Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2023: €898.8 MM, 1900 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.

Almirall成立于1944年，总部位于巴塞罗那，在西班牙证券交易所公开交易（股票代码：ALM，2023年总收入：8.988亿欧元，全球员工1900人）。衣橱产品每天都有助于改善患者的生活，并在100多个国家/地区提供。

For more information, please visit https://www.almirall.com/

For more information, please visit https://www.almirall.com/

Legal notice:

法律公告：

This document includes only summary information and is not intended to be exhaustive. The facts, figures, and opinions contained in this document, in addition to the historical ones, are 'forward-looking statements.' These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable.

本文件仅包含摘要信息，并非详尽无遗。本文件中包含的事实、数字和观点，除了历史性的之外，都是“前瞻性的陈述”这些报表基于目前可用的信息以及公司认为合理的最佳估计和假设。

These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals, or estimates contained in this document to reflect any changes in the assumptions, events, or circumstances on which such forward-looking statements are based, unless required by the applicable law..

这些报表涉及公司无法控制的风险和不确定性。因此，实际结果可能与此类前瞻性声明所宣布的结果存在重大差异。除非适用法律要求，否则公司明确放弃修改或更新本文件中包含的任何前瞻性声明、目标或估计的任何义务，以反映此类前瞻性声明所依据的假设、事件或情况的任何变化。。